Avenue Therapeutics, Inc. (ATXI)
US — Healthcare Sector
Automate Your Wheel Strategy on ATXI
With Tiblio's Option Bot, you can configure your own wheel strategy including ATXI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATXI
- Rev/Share 0.0
- Book/Share 0.785
- PB 0.2196
- Debt/Equity 0.0
- CurrentRatio 2.775
- ROIC -4.228
- MktCap 826144.0
- FreeCF/Share -2.3872
- PFCF -0.1165
- PE -0.0564
- Debt/Assets 0.0
- DivYield 0
- ROE -3.9933
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Avenue Therapeutics, Inc. (ATXI)
- IPO Date 2017-06-27
- Website https://www.avenuetx.com
- Industry Biotechnology
- CEO Dr. Alexandra MacLean M.D.
- Employees 2
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.